Erasca, Inc. (ERAS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Erasca, Inc. (ERAS) closed at USD 14.70 on 2026-10-14, a change of +502.5 % over the past year, with a market capitalization of USD 5.2B.

Erasca, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Erasca, Inc. key figures

Previous close

USD 14.70 (2026-10-14)

1-year change

+502.5 %

Market cap

USD 5.2B

Enterprise value

USD 4.98B

P/E ratio (trailing)

-15.65

P/E ratio (forward)

-23.86

EPS (trailing)

-0.95

EPS (forward)

-0.62

PEG ratio

n/a

Price to book

12.84

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.32

Employees

103

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Erasca, Inc.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Erasca, Inc. and compare it with other stocks.